Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

Emergent Biosolutions (EBS)

Emergent Biosolutions Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:EBS
DateTimeSourceHeadlineSymbolCompany
17/09/202421:12Edgar (US Regulatory)Form 8-K - Current reportNYSE:EBSEmergent Biosolutions Inc
13/09/202411:45GlobeNewswire Inc.Emergent BioSolutions Announces Agreement to Settle Securities Class Action LitigationNYSE:EBSEmergent Biosolutions Inc
12/09/202413:30GlobeNewswire Inc.Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for EbolaNYSE:EBSEmergent Biosolutions Inc
03/09/202412:47Edgar (US Regulatory)Form 8-K - Current reportNYSE:EBSEmergent Biosolutions Inc
03/09/202412:08GlobeNewswire Inc.Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial ProfileNYSE:EBSEmergent Biosolutions Inc
30/08/202413:16GlobeNewswire Inc.Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency PreparednessNYSE:EBSEmergent Biosolutions Inc
29/08/202423:53GlobeNewswire Inc.Emergent BioSolutions’ ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other RegionsNYSE:EBSEmergent Biosolutions Inc
20/08/202421:20Edgar (US Regulatory)Form 8-K - Current reportNYSE:EBSEmergent Biosolutions Inc
20/08/202416:30GlobeNewswire Inc.Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora PharmaceuticalsNYSE:EBSEmergent Biosolutions Inc
19/08/202422:10GlobeNewswire Inc.Emergent BioSolutions Responds to Mpox Public Health Emergency as Cases Surge in AfricaNYSE:EBSEmergent Biosolutions Inc
06/08/202422:01GlobeNewswire Inc.Emergent BioSolutions Reports Second Quarter 2024 Financial ResultsNYSE:EBSEmergent Biosolutions Inc
06/08/202421:34Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNYSE:EBSEmergent Biosolutions Inc
06/08/202421:21Edgar (US Regulatory)Form 8-K - Current reportNYSE:EBSEmergent Biosolutions Inc
06/08/202413:00GlobeNewswire Inc.Emergent BioSolutions Expands NARCAN® Nasal Spray Distribution Capabilities to Enhance Customer Delivery Experience Across the CountryNYSE:EBSEmergent Biosolutions Inc
31/07/202413:56Edgar (US Regulatory)Form 8-K - Current reportNYSE:EBSEmergent Biosolutions Inc
31/07/202413:53GlobeNewswire Inc.Emergent BioSolutions Completes Sale of RSDL® (Reactive Skin Decontamination Lotion) Kit to SERB Pharmaceuticals for $75 MillionNYSE:EBSEmergent Biosolutions Inc
30/07/202421:30Edgar (US Regulatory)Form 8-K - Current reportNYSE:EBSEmergent Biosolutions Inc
24/07/202412:30GlobeNewswire Inc.Emergent BioSolutions Launches Opioid Emergency Preparedness ‘Lay, Spray, Stay’ Public Education Campaign Starring Pro Football Hall of Famer Emmitt SmithNYSE:EBSEmergent Biosolutions Inc
23/07/202413:27GlobeNewswire Inc.Emergent BioSolutions to Release Second Quarter 2024 Financial Results & Conduct Conference Call on August 6, 2024NYSE:EBSEmergent Biosolutions Inc
22/07/202413:00GlobeNewswire Inc.Emergent BioSolutions Announces Shelf-Life Extension for NARCAN® Nasal Spray in CanadaNYSE:EBSEmergent Biosolutions Inc
12/07/202421:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:EBSEmergent Biosolutions Inc
12/07/202421:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:EBSEmergent Biosolutions Inc
10/07/202421:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:EBSEmergent Biosolutions Inc
09/07/202412:30GlobeNewswire Inc.Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation PlanNYSE:EBSEmergent Biosolutions Inc
08/07/202421:57Edgar (US Regulatory)Form 8-K - Current reportNYSE:EBSEmergent Biosolutions Inc
02/07/202414:43GlobeNewswire Inc.Update: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure ProductsNYSE:EBSEmergent Biosolutions Inc
02/07/202413:13GlobeNewswire Inc.Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure ProductsNYSE:EBSEmergent Biosolutions Inc
20/06/202412:05Edgar (US Regulatory)Form 8-K - Current reportNYSE:EBSEmergent Biosolutions Inc
20/06/202412:00GlobeNewswire Inc.Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 MillionNYSE:EBSEmergent Biosolutions Inc
11/06/202421:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:EBSEmergent Biosolutions Inc
 Showing the most relevant articles for your search:NYSE:EBS

Your Recent History

Delayed Upgrade Clock